Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity
Elisabetta Gambale1, Anna Boddi2, Adriano Pasqui3
1Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Abstract:
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics. Therefore, the detection of pharmacogenomics (PGx) biomarkers that might predict drug response and toxicity can be useful to explain the genetic basis for the differences in treatment efficacy and toxicity among STS patients. PGx markers are frequently located in transporters, drug-metabolizing enzyme genes, drug targets, or HLA alleles. Along this line, genetic variability harbouring in the germline genome of the patients can influence systemic pharmacokinetics and pharmacodynamics of the treatments, acting as predictive biomarkers for drug-induced toxicity and treatment efficacy. By linking drug activity to the functional complexity of cancer genomes, also systematic pharmacogenomic profiling in cancer cell lines and primary STS samples represents area of active investigation that could eventually lead to enhanced efficacy and offer a powerful biomarker discovery platform to optimize current treatments and improve the knowledge about the individual's drug response in STS patients into the clinical practice.
Insights
Pharmacogenomics (PGx) biomarkers can predict treatment efficacy and toxicity in soft tissue sarcoma (STS) patients. Identifying these genetic markers helps personalize cancer therapy, improving outcomes and reducing adverse effects for individuals.
Area of Science:
- Oncology
- Pharmacogenomics
- Genetics
Background:
- Clinical responses to advanced soft tissue sarcoma (STS) therapies vary significantly among patients.
- Inter-individual differences in treatment efficacy and toxicity are often linked to genetic variations affecting drug metabolism and action.
Purpose of the Study:
- To highlight the utility of pharmacogenomics (PGx) biomarkers in predicting drug response and toxicity in STS.
- To explore the genetic basis for variable treatment outcomes in STS patients.
Main Methods:
- Investigating polymorphisms in genes encoding drug transporters, metabolizing enzymes, and drug targets.
- Analyzing germline genetic variability influencing drug pharmacokinetics and pharmacodynamics.
- Systematic pharmacogenomic profiling in STS cell lines and primary samples.
Main Results:
- Pharmacogenomic markers, including those in transporter, enzyme, and HLA genes, can predict treatment efficacy and toxicity.
- Germline genetic variations significantly impact drug pharmacokinetics and pharmacodynamics, serving as predictive biomarkers.
- Linking drug activity with cancer genome complexity is a key area for biomarker discovery.
Conclusions:
- Pharmacogenomic profiling offers a powerful platform for discovering biomarkers to optimize STS treatments.
- Understanding individual genetic profiles can enhance treatment efficacy and reduce toxicity in STS patients.
- Integrating PGx knowledge into clinical practice can improve personalized medicine approaches for STS.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution